FDA approves Roche Tecentriq combination as first adjuvant immunotherapy for stage III dMMR colon cancer

The FDA has approved Roche's Tecentriq-based chemotherapy regimen as the first adjuvant immunotherapy option for eligible patients with stage III mismatch repair-deficient colon cancer.

The approval covers Tecentriq (atezolizumab) and Tecentriq Hybreza in combination with fluoropyrimidine and oxaliplatin chemotherapy for adjuvant treatment of stage III dMMR colon cancer.

In the Phase III ATOMIC trial, the immunotherapy combination reduced the risk of disease recurrence or death by 50% compared with chemotherapy alone, establishing a new treatment option following surgery.

Field	Content
Article Type	Approvals
Drug Names	Tecentriq; Tecentriq Hybreza
Generic Name	Atezolizumab
Company	Roche
Regulatory Authority	U.S. Food and Drug Administration
Approval Type	New adjuvant treatment indication
Indication	Stage III mismatch repair-deficient colon cancer
Patient Population	Eligible patients with stage III dMMR colon cancer
Therapy Area	Oncology; colorectal cancer
Technology/Modality	PD-L1 checkpoint inhibitor immunotherapy
Approved Regimen	Atezolizumab or atezolizumab and hyaluronidase-tqjs in combination with fluoropyrimidine and oxaliplatin chemotherapy
Treatment Setting	Adjuvant treatment following surgery
Clinical Study	Phase III ATOMIC
Key Clinical Finding	50% reduction in the risk of disease recurrence or death compared with chemotherapy alone
Biomarker	Mismatch repair deficiency (dMMR)
Geography	United States
What Happened	The FDA approved Tecentriq and Tecentriq Hybreza in combination with fluoropyrimidine and oxaliplatin chemotherapy for adjuvant treatment of eligible patients with stage III dMMR colon cancer.
Why It Matters	The decision establishes the first approved adjuvant immunotherapy regimen for stage III dMMR colon cancer and introduces a biomarker-directed treatment option in this setting.
Supporting Context	The Phase III ATOMIC study demonstrated a 50% reduction in the risk of recurrence or death with the atezolizumab-containing regimen compared with chemotherapy alone.
Potential Impact	The approval could change postoperative treatment pathways for eligible patients with stage III dMMR colon cancer.
Key Takeaway	Roche has secured FDA approval for a Tecentriq-based adjuvant regimen in stage III dMMR colon cancer following positive Phase III ATOMIC results.
What to Watch	Updated oncology guidelines, biomarker testing practices, clinical adoption, reimbursement and longer-term survival outcomes.
Primary Source	Roche
Relevant Date	8 October 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com